O mastologista Sílvio Bromberg e o oncologista Daniel Gimenes comentam algumas das publicações de alto impacto que estiveram entre os hot topics da oncologia mamária em janeiro. Afinal, qual a utilidade do escore Oncotype DX no manejo clínico de pacientes com câncer de mama receptor estrogênio positivo e linfonodo negativo? E a concordância entre os escores de recorrência de 21 genes no câncer de mama multifocal, difere com a idade e o subtipo histológico? Acompanhe essas e outras questões no Podcast Onconews.
Referências:
- Nguyen TTA, Postlewait LM, Zhang C, Meisel JL, O'Regan R, Badve S, Kalinsky K, Li X. Utility of Oncotype DX score in clinical management for T1 estrogen receptor positive, HER2 negative, and lymph node negative breast cancer. Breast Cancer Res Treat. 2022 Jan 27. doi: 10.1007/s10549-022-06530-6. Epub ahead of print. PMID: 35084624.
- Pawloski KR, Wen HY, Tadros AB, Abbate K, Morrow M, El-Tamer M. Concordance Between 21-Gene Recurrence Scores in Multifocal or Multicentric Breast Carcinomas Differs by Age and Histologic Subtype. Ann Surg Oncol. 2021 Aug;28(8):4256-4262. doi: 10.1245/s10434-020-09429-y. Epub 2021 Jan 3. PMID: 33393037; PMCID: PMC8253864.
- Mamtani A, Sevilimedu V, Vincent A, Morrow M. Local Recurrence is Frequent After Heroic Mastectomy for Classically Inoperable Breast Cancers. Ann Surg Oncol. 2022 Feb;29(2):1043-1048. doi: 10.1245/s10434-021-10764-x. Epub 2021 Sep 14. PMID: 34522999.
- Anderson, R.A., Kelsey, T.W., Perdrix, A. et al. Diagnostic and predictive accuracy of anti-mullerian hormone for ovarian function after chemotherapy in premenopausal women with early breast cancer. Breast Cancer Res Treat (2022). https://doi.org/10.1007/s10549-021-06508-w
--
